Fig. 4
From: Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells
Cell cycle progression analysis of vorinostat in combination with cisplatin in SCLC cells. a H209 and b H146 cells were treated with vorinostat (0.1 μM), cisplatin alone (5 μM), and a combination of these 2 agents for 24 h, and the cell cycle distribution was analyzed through flow cytometry. c, d Statistical analysis of cell cycle distribution was represented as mean ± SD in 3 independent studies. A significant arrest in the cell-cycle phase was documented (*, P < 0.05; **, P < 0.01) compared with that in DMSO